
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
BCM-95 (Curcugreen) is a patented curcumin extract that combines curcumin with turmeric essential oils to increase bioavailability by up to 700% compared to standard curcumin. It delivers enhanced anti-inflammatory effects by inhibiting nuclear factor-kappa B (NF-κB) signaling pathways more effectively than regular curcumin supplements.

Reported Benefits (Provisional)
Origin & History

BCM-95, also known as Curcugreen, is a patented form of curcumin that combines curcumin with essential oils from turmeric for enhanced absorption. It is produced through a unique process that retains the natural profile of the turmeric root.
Research Narrative (Provisional)
Research, including RCTs, indicates that BCM-95 offers superior bioavailability compared to standard curcumin. Meta-analyses support its role in promoting joint health and reducing inflammation.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
BCM-95 (Curcugreen) is a standardized curcumin complex containing approximately 86% total curcuminoids (curcumin, bisdemethoxycurcumin, and demethoxycurcumin) combined with turmeric-derived essential oils (ar-turmerone, α-turmerone, β-turmerone) at roughly 7-9% concentration. It contains no significant macronutrients, vitamins, or minerals in functional quantities. The bioactive core is curcumin (typically ~75-80% of the curcuminoid fraction), which in standard turmeric extract has poor oral bioavailability (<1%), but BCM-95's essential oil matrix inhibits curcumin crystallization and enhances intestinal absorption, yielding approximately 6.93-fold greater bioavailability compared to unformulated 95% curcumin extract. Unlike piperine-enhanced formulas, BCM-95 achieves this without cytochrome P450 enzyme inhibition. Plasma curcumin levels of ~200-400 ng/mL have been measured post-supplementation at typical doses of 500-1000 mg.
Reported Mechanism (Provisional)
BCM-95 curcumin inhibits nuclear factor-kappa B (NF-κB), a key inflammatory transcription factor, while simultaneously blocking cyclooxygenase-2 (COX-2) and lipoxygenase enzymes. The patented combination with turmeric essential oils containing ar-turmerone enhances intestinal absorption and prevents rapid metabolism by phase II detoxification enzymes. This dual approach maintains higher plasma curcumin levels for extended periods, allowing sustained modulation of inflammatory cytokines like TNF-α and interleukin-6.
Clinical Narrative (Provisional)
Human studies on BCM-95 include randomized controlled trials with 40-100 participants showing significant improvements in joint pain and mobility scores within 8-12 weeks. A 2014 study demonstrated 58% reduction in pain and stiffness compared to 2% with diclofenac in osteoarthritis patients taking 500mg twice daily. Bioavailability studies confirm 6.93-fold higher plasma curcumin levels compared to standard curcumin extracts. However, most clinical trials are relatively small and short-term, requiring larger long-term studies for definitive therapeutic claims.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







